Topic is suspended
Status Suspended
Decision Selected
Process TA
ID number 3861


Key events during the development of the guidance:

Date Update
08 January 2021 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
08 January 2021 Suspended. Topic is suspended

For further information on our processes and methods, please see our CHTE processes and methods manual